Ox­ford Bio­med­ica, San­ten ink gene ther­a­py pact; DayT­wo rais­es $31M in Se­ries B round

→ British gene and cell ther­a­py com­pa­ny Ox­ford Bio­med­ica {LSE: $OXB} is join­ing forces with Japan’s San­ten Phar­ma­ceu­ti­cal to de­vel­op gene ther­a­pies for in­her­it­ed reti­nal dis­eases. Ox­ford is en­ti­tled to an undis­closed mile­stone pay­ment on the ex­er­cise of the op­tion to the LentiVec­tor plat­form, as well as de­vel­op­men­tal mile­stones and up to a 10% roy­al­ty on net sales.

→ DayT­wo — a mi­cro­bio­me com­pa­ny that cham­pi­ons the “food-as-med­i­cine” ap­proach to help pre-di­a­bet­ics and di­a­bet­ics bal­ance their blood glu­cose — has raised $31 mil­lion in a Se­ries B round of fi­nanc­ing, co-led by VC’s aMoon and Ofek Ven­tures and par­tic­i­pa­tion from ex­ist­ing in­vestors Sev­en­ture Part­ners and John­son & John­son $JNJ.  The fi­nanc­ing brings DayT­wo’s to­tal fund­ing to $48 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER